161 results about "Pediococcus sp." patented technology

The invention discloses pediococcus acidilactici and application thereof, and relates to the technical field of microorganisms. The pediococcus acidilactici is pediococcus acidilactici Mei.1103.1, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC NO.32564, the preservation date is November 11, 2024, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1 is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1. The invention also provides application of the fermented dry rice flour in preparation of products for reducing uric acid, preventing / treating hyperuricemia, regulating immunity, preventing / treating kidney injury and preventing / treating fatty liver and fermented dry rice flour. The bacterium can reduce uric acid and relieve hyperuricemia; regulating blood fat; kidney and liver injuries caused by hyperuricemia are repaired; the content of volatile flavor compounds in the fermented dry rice flour is increased.

The invention discloses pediococcus pentosaceus CCFM1402 capable of effectively repairing a skin barrier and a self-fermentation metabolite of the pediococcus pentosaceus CCFM1402, and belongs to the technical field of microorganisms and medicines. The pediococcus pentosaceus CCFM1402 provided by the invention has the effect of improving the skin barrier function in both external use and oral administration; the cell activity of damaged HaCaT cells and the expression of the gene level of skin barrier function protein and tight junction protein can be improved by virtue of a thallus lysate and a fermented supernatant (metagen) of the external pediococcus pentosaceus CCFM1402; and the DNFB-induced mouse skin barrier injury can be relieved in the aspects of appearance, skin barrier protein expression and the like by orally taking viable bacteria and postbiotics of the pediococcus pentosaceus CCFM1402. Therefore, the pediococcus pentosaceus CCFM1402 has a huge application prospect in preparation of external or oral medicines for repairing the skin barrier and preparation of food, health care products or cosmetics.

The invention belongs to the technical field of microorganisms, and particularly relates to probiotic characteristics of lactic acid bacteria and a relieving effect of a metagen of the lactic acid bacteria on pulmonary fibrosis. The invention discloses pediococcus pentosaceus ZFML001, and the preservation number of the pediococcus pentosaceus ZFML001 is CCTCC (China Center for Type Culture Collection) NO: M 2024601. The invention also provides a metagen prepared from the pediococcus pentosaceus ZFML001 at the same time, and provides an application of the metagen in preparation of a medicine for relieving or assisting in treatment of pulmonary fibrosis. The invention further provides the application of the metagen in preparation of a medicine for relieving or assisting in treatment of pulmonary fibrosis.

The invention discloses pediococcus acidilactici NDF12 and application thereof, the pediococcus acidilactici NDF12 is preserved in Guangdong Microbial Culture Collection Center on January 8, 2025, is called GDMCC for short, and the preservation number is GDMCC NO: 65732. The invention further discloses a preparation method of the pediococcus acidilactici NDF12. The strain is derived from Chinese local traditional dairy products, phenotype and genotype safety evaluation proves that the strain is safe and non-toxic, has excellent fermentation characteristics and probiotic characteristics, and can be used as a leavening agent for producing yoghourt. The bacterial strain also has gastrointestinal fluid endurance capacity, adhesion capacity, bacteriostatic activity, antioxidant activity, cholesterol lowering activity and blood sugar lowering activity, and has great application prospects in the fields of foods, medicines, feeds and the like.

The invention relates to pediococcus acidilactici XZ106, which is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30094, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici XZ106 can (1) relieve insulin resistance, regulate insulin and glucagon secretion and improve liver gluconeogenesis, so that diabetes hyperglycemia is improved; (2) weight gain, fat accumulation and liver lipid accumulation of obese mice are inhibited, glycolipid metabolism disorder of the mice is improved, and the composition has excellent effects of reducing fat and relieving obesity; (3) the level of IL-10 can be remarkably improved, and the anti-inflammatory ability of mice is improved; (4) vascular injury is reduced, so that diabetic complications and various cardiovascular diseases of atherosclerosis are prevented.

The invention discloses pediococcus acidilactici JW-015 as well as a selenium-rich microbial inoculum and application thereof, and belongs to the technical field of biology. According to the invention, a strain of pediococcus JW-015 which not only can be enriched with inorganic selenium, but also has oxidation resistance and ethanol tolerance is screened out, and the pediococcus JW-015 has huge potential and application value in the aspect of developing hangover-alleviating related probiotic health-care foods and medicines.

The invention relates to the technical field of microbial fermentation, in particular to a preparation method of a glucose fermentation product with bacteriostatic activity, which comprises the following steps: (1) inoculating a lactococcus lactis subsp. Lactis seed solution into a glucose-containing fermentation culture solution, and fermenting to obtain a first fermentation solution; (2) inoculating a pediococcus acidilactici seed solution into the first fermentation liquor, supplementing glucose, and fermenting to obtain second fermentation liquor; and (3) adjusting the pH value of the second fermentation liquor to be acidic, filtering, concentrating, and spray-drying to obtain the glucose fermentation product. According to the invention, the characteristic that organic acids and bacteriocin generated by lactococcus lactis subsp. Lactis and pediococcus acidilactici are different in types is fully utilized, metabolites of the two bacteria are obtained at the same time by adopting a sequential sequence type fermentation mode, and the metabolites of the lactococcus lactis subsp. Lactis are converted by pediococcus acidilactici, so that a new substance with bacteriostatic activity is obtained; the antibacterial activity is improved. Meanwhile, the problem of nutrition competition caused by mixed culture of the two bacteria is avoided, and the fermentation efficiency is improved.

The present invention provides a Pediococcus pentosaceus ( Pediococcus pentosus ) strain ZPP083, which is deposited with the General Microbiology Center of the China National Center for Microbiological Culture Collection under the CGMCC No. 31944. The Pediococcus pentosaceus provided by the present invention has a strong antibacterial effect and produces a novel Class IIa bacteriocin with acid, heat, and protease resistance. The present invention also constructs a genetically engineered bacterium using this bacteriocin, increasing its expression.

The invention relates to a lactic acid bacterium capable of reducing fat, resisting inflammation and reducing blood sugar, which is classified and named as pediococcus acidilactici XJ335, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30093, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can achieve the fat reducing effect by adjusting the abundance of intestinal flora; the levels of IL-6 and TNF-alpha in serum of diabetic mice are remarkably improved through regulation, so that the anti-inflammatory effect is achieved; various cardiovascular diseases of atherosclerosis are prevented by adjusting the levels of TC, TG, HDL-C and LDL-C; by reducing FINS and HOMA-IR levels and improving HOMA-IS, HOMA-beta and QUICKI value levels, insulin resistance of a body is reduced, insulin sensitivity and pancreas islet beta cell functions of the body are improved, gene expression related to blood sugar regulation is regulated, and an excellent blood sugar reducing effect is achieved in the body.

The invention relates to uric acid reducing probiotics obtained by high-throughput screening based on a silkworm model, in particular to a strain SWU-MY69, which is classified and named as Pediococcus pentosaceus, is preserved in China General Microbiological Culture Collection Center (CGMCC), has a preservation number of CGMCC No.31926, and is preserved in September 10, 2024. The pediococcus pentosaceus SWU-MY69 screened through a bombyx mori model has an excellent uric acid reducing effect, the inhibition rates of bacterial suspension, contents and metabolites of the strain on xanthine oxidase in vitro are all 80% or above, and the pediococcus pentosaceus SWU-MY69 also has an excellent inhibition effect on xanthine oxidase in vivo; uric acid in hemolymph is remarkably reduced, excretion of uric acid by intestinal tracts is promoted, and therefore the concentration of uric acid in serum is reduced, and burdens of kidneys and livers are reduced.

The invention belongs to the technical field of probiotics, and particularly relates to pediococcus acidilactici with acid resistance, bile salt resistance and antibacterial activity and application of the pediococcus acidilactici. The pediococcus acidilactici TR19 has the preservation number of CGMCC NO.31330 and is classified and named as pediococcus acidilactici according to microorganisms. The strain has good acid resistance and bile salt resistance, and can be used for preparing probiotics for preventing and treating bacteria. Meanwhile, the strain has a relatively strong bacteriostatic effect on escherichia coli, bacillus cereus, staphylococcus aureus and salmonella typhimurium, in addition, the strain has a relatively good degradation capability on nitrite and cholesterol, and the applicability is relatively strong.

The invention provides an application of a pediococcus pentosaceus strain A20001 in preparation of a product for improving memory concentration and anxiety and depression behaviors, and belongs to the technical field of biological medicines. Animal experiments show that the pediococcus pentosaceus strain A20001 has the functions of resisting anxiety behavior, resisting depression, improving cognitive function and improving memory concentration. Therefore, the invention provides the application of the pediococcus pentosaceus strain A20001 in the preparation of the medicine for preventing and / or treating the anxiety disorder, the depression or the cognitive impairment and improving the memory, and further provides the application of the pediococcus pentosaceus strain A20001 in the preparation of the medicine for preventing and / or treating the anxiety disorder, the depression or the cognitive impairment.

The invention discloses pediococcus acidilactici screening and application of pediococcus acidilactici in reducing allergenicity of whey and improving flavor, and belongs to the technical field of whey processing. The invention provides a Pediococcus acidilactici BC37, and the preservation number of the Pediococcus acidilactici BC37 is GDMCC No: 66262. The Pediococcus acidilactici BC37 can be used for preparing a Pediococcus acidilactici strain. When the pediococcus acidilactici BC37 is used for preparing the fermented whey, beta-lactoglobulin and lactose in the whey can be effectively degraded, and the degradation rates respectively reach 49.93% and 15.74%; meanwhile, after whey is fermented by the pediococcus acidilactici BC37, high-content flavor substances such as furfural, butyric acid and ethyl caprate are generated. Therefore, the pediococcus acidilactici BC37 provided by the invention has a great industrial application prospect in preparation of fermented whey products with low sensitization and unique flavor.

This invention belongs to the field of microbial technology, specifically relating to a strain of *Pediococcus pentosaceus* SUN02 with acetylcholinesterase inhibitory activity and its applications. This *Pediococcus pentosaceus* SUN02 is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 29705. The *Pediococcus pentosaceus* SUN02 provided by this invention exhibits strong acid and bile salt resistance, good tolerance in simulated gastric and intestinal fluids, and can successfully reach the human intestine. *Pediococcus pentosaceus* SUN02, in its bacterial suspension and inactivated cells, possesses strong acetylcholinesterase inhibitory activity, produces γ-aminobutyric acid (GABA), and has antioxidant and other probiotic functions. Its application in probiotic products may help improve Alzheimer's disease, enhance learning and memory abilities, regulate mood, and improve sleep.

The invention relates to pediococcus acidilactici, in particular to pediococcus acidilactici TCI550 with the preservation number of DSM34536, and the pediococcus acidilactici TCI550 has the preservation number of DSM34536. In addition, the pediococcus acidilactici TCI550 and / or metabolites thereof can be suitable for preparing a composition for nerve health care and / or cognition improvement.

The invention relates to the technical field of functional microbial preparations, in particular to a biological preparation for relieving intestinal discomfort caused by alcohol and a preparation method and application thereof.The main technical scheme is that the biological preparation is prepared from, by weight, 5-20 parts of bacillus coagulans, 10-30 parts of pediococcus pentosaceus, 5-10 parts of lactobacillus rhamnosus and 0-20 parts of saccharomycetes. 0-5 parts of bifidobacterium longum and 0-5 parts of lactococcus lactis. By constructing an alcohol metabolism-intestinal protection dual-function synergistic system, specific florae such as bacillus coagulans, pediococcus pentosaceus and lactobacillus rhamnosus are scientifically compatible with functional components such as inulin and L-cysteine, alcohol is efficiently metabolized, and a carbon source is generated; the technical problems of low metabolic efficiency, weak intestinal protection and serious gastric acid inactivation of a traditional product are comprehensively solved.

The invention relates to the technical field of probiotics, in particular to pediococcus acidilactici ZKPa1222, astragalus mongholicus fermentation liquor of the pediococcus acidilactici ZKPa1222 and application of the pediococcus acidilactici ZKPa1222 in the aspect of improving immunity, the pediococcus acidilactici ZKPa1222 is preserved in China General Microbiological Culture Collection Center on May 13, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC No.30548, and the preservation number is CGMCC No.30548. The invention further discloses a preparation method of the pediococcus acidilactici ZKPa1222. According to the invention, the pediococcus acidilactici ZKPa1222 is used for directly fermenting the radix astragali extracting solution, so that the fermentation process is simplified, and the fermentation efficiency is improved.

The invention belongs to the technical field of functional microorganisms, and provides pediococcus acidilactici MR21 and application thereof. The pediococcus acidilactici MR21 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 3, 2024, and the preservation number is CGMCC NO. 32896. The pediococcus acidilactici MR21 disclosed by the invention has efficient in-vitro cholesterol removal capacity, excellent safety and remarkable probiotic characteristics, and has the effects of restoring liver functions, reducing liver fat accumulation and regulating expression of fat and cholesterol metabolism related genes by remarkably reducing the content of serum total cholesterol and low-density lipoprotein cholesterol. Therefore, the function of relieving hypercholesterolemia is achieved.

This invention belongs to the field of food fermentation technology, and specifically relates to a compound probiotic agent and its application in the preparation of fermented soy milk. This invention provides a compound probiotic agent composed of *Lactobacillus fermentum* NCPS LF01, *Pediococcus pentosaceus* NCPS PPE01, and *Lactobacillus acidophilus* NCPS LA01 in a volume ratio of 1-2:1:1, and applies this compound probiotic agent to the preparation of soy products, especially fermented soy milk. The beneficial effects of this invention are that fermented soy milk prepared using this compound probiotic agent has a rich flavor, and the total flavonoid and total phenolic content, as well as the in vitro DPPH free radical scavenging rate, are significantly superior to those of ordinary commercially available strains or other strains. In summary, this compound probiotic agent can effectively improve the retention level of active ingredients and antioxidant capacity of fermented soy milk, and has outstanding application value.

The invention discloses pediococcus acidilactici and application thereof in preparation of a medicine for preventing or treating diarrhea of yak calves, and belongs to the technical field of microorganisms. The pediococcus acidilactici is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: M20252012, and the preservation date is September 12, 2025. The strain has remarkable bacteriostatic activity on yak-derived multi-drug-resistant escherichia coli (the accession number of NCBI is PP859186). After the probiotic preparation is orally taken, the yak calf diarrhea induced by escherichia coli can be effectively relieved, the diarrhea rate and the inflammatory factor level are remarkably reduced, the oxidation resistance is improved, the flora structures of intestinal bacteria and fungi are adjusted, and the micro-ecological balance is restored. The invention provides a safe, green and efficient alternative antibody product which is suitable for the plateau yak breeding industry.

The microorganism strain Pediococcus acidilactici TAK 589 CoccobEst is a new antimicrobial and antioxidant probiotic, CoccobEst inhibits the growth of the enteropathogens L. monocytogenes, E. coli, S. enteritidis, S. typhimurium, S. sonnei, S. aureus, E. faecalis and C. sakazakii, but does not inhibit lactobacilli of natural intestinal microbiota. The strain's antimicrobial properties are enhanced by periplasmic peptidoglycan hydrolases with proteolytic activity. CoccobEst is used as a zootechnieai feed additive to prevent bacterial infections in the gastrointestinal tract of farm animals and pets and to prevent and reduce diarrhea. CoccobEst has highly active antioxidant defense system, increasing the redox activity of glutathione and reducing oxidative stress in cells. Therefore, CoccobEst is used as a food supplement or functional food for humans to prevent bacterial infections of the gastrointestinal tract and to prevent and reduce oxidative stress. In addition, CoccobEst is used as a starter culture in fermentation of vegetables.

The invention relates to the technical field of raw materials of skin care products, and particularly discloses a soothing and moisturizing compound as well as a preparation method and application thereof. The preparation method of the soothing and skin-moistening compound comprises the following steps: 1) mixing rice, cornflower, quisqualis indica, cashew nut and water, heating and extracting to obtain a pre-extract; (2) adding compound bacteria into the pre-extract, and fermenting to obtain a fermented product; the invention discloses a soothing and skin-moistening compound and a preparation method thereof.The soothing and skin-moistening compound has the advantages that the soothing and skin-moistening compound is prepared from compound bacteria of streptomyces cinereorubens fructose fermentation subspecies, fermented lactobacillus mucus and pediococcus pentosaceus, and the soothing and skin-moistening compound is more remarkable in soothing effect.

This invention discloses a multifunctional Pediococcus pentosaccharide strain and its applications. Pediococcus pentosaceus The strain, named *Pediococcus pentosaceus* A07, has the accession number CCTCC NO: M 2025777 and is deposited at the China Center for Type Culture Collection (CCTCC), located at Wuhan University, No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province. This strain is capable of degrading nitrite. Using *Pediococcus pentosaceus* A07 to reduce nitrite content can produce high-quality pickles with good flavor and texture, low nitrite content, and high viable cell count. The *Pediococcus pentosaceus* A07 provided by this invention also possesses cholesterol-lowering, zinc protoporphyrin-forming, antibacterial, and antioxidant capabilities, and produces a high biofilm.

The invention discloses a pediococcus pentosaceus MDL511, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 has the advantages that the preservation number is CGMCC No.35201, the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 disclosed by the invention can be used for remarkably reducing weight gain and fat growth of mice caused by high fat diet, reducing serum cholesterol, LDL-C (Low Density Lipoprotein Cholesterol) and ALT (Atomic Lymphocyte Transferase) levels and remarkably improving hepatic lesions and fat accumulation caused by high fat diet, so that the MDL511 has a blood fat reducing effect, can be used for preparing blood fat reducing products and weight losing products and has a good development prospect.

The invention relates to the technical field of microbial food fermentation, and particularly discloses pediococcus acidilactici RM1, a separation method and application, and the pediococcus acidilactici RM1 is characterized in that the preservation number of the pediococcus acidilactici RM1 is GDMCC NO.66765; the preservation unit of the pediococcus acidilactici RM1 is Guangdong Microbial Culture Collection Center; the preservation name of the pediococcus acidilactici RM1 is pediococcus acidilactici RM1, and the preservation name of the pediococcus acidilactici RM1 is pediococcus acidilactici RM1. The preservation time of the pediococcus acidilactici RM1 is July 28, 2025. The method has the characteristics of bright red color, difficulty in deterioration during storage and ideal quality and flavor.

The invention discloses a probiotic composition, fermented yoghurt and application of the probiotic composition and the fermented yoghurt in improving related indexes of athletes. The probiotic composition comprises bacillus subtilis SP-8-5, lactobacillus plantarum YM-4-3, lactobacillus plantarum AY01 and pediococcus acidilactici LH01. The composition of intestinal microbial populations can be adjusted through a specific compounding method, the abundance of harmful bacteria is reduced, the abundance of beneficial bacteria is improved, the immunity of intestinal tracts is enhanced, and the integrity of intestinal barriers of athletes is maintained. Meanwhile, the composition has a positive improvement effect on related exercise indexes such as plasma amino acid, excrement metabolites and exercise performance, and can be used as an effective exercise supplement to be applied to athletes.

The present invention belongs to the field of microbial technology, and specifically relates to the probiotic properties of lactic acid bacteria and the alleviating effect of their postbiotics on pulmonary fibrosis. Pediococcus pentosaceus ) ZFML001, whose deposit number is CCTCC NO: M 2024601. The present invention also provides a method for using the above-mentioned Pediococcus pentosaceus ( Pediococcus pentosaceus ) A postbiotic prepared by ZFML001, and use of the postbiotic in preparing a drug for alleviating or assisting in the treatment of pulmonary fibrosis.

The invention relates to a compound vomitoxin detoxification agent as well as a preparation method and application thereof, and belongs to the field of feed additives. The compound vomitoxin detoxification agent comprises the following components: detoxification bacteria, glucose oxidase, an adsorbent and a eucommia ulmoides extract, the detoxification bacteria are lactobacillus plantarum, pediococcus pentosaceus and saccharomyces cerevisiae. The compound vomitoxin detoxification agent can effectively reduce DON toxins in feed, improve the antioxidant capacity of animals, improve immunity, regulate intestinal flora and promote animal growth.

The invention provides pediococcus acidilactici SCFF996 with high EutE enzyme activity and application of the pediococcus acidilactici SCFF996 in a hangover alleviating and liver protecting product, and belongs to the technical field of microorganisms. Wherein the pediococcus acidilactici SCFF996 is preserved in the China General Microbiological Culture Collection Center, and the preservation number of the pediococcus acidilactici SCFF996 is CGMCC (China General Microbiological Culture Collection Center) No. 33405. The pediococcus acidilactici SCFF996 provided by the invention has very good EutE enzyme activity, ethanol tolerance, acid resistance and cholate resistance, can inhibit pathogenic bacteria, is easy to culture and high in reproduction speed, and has remarkable advantages in production of alcohol effect dispelling and liver protecting products.

A probiotic lactic acid bacteria, classified as Pediococcus acidilactici ( Pediococcus acidilactici ) XJ‑24, deposited in China General Microbiological Culture Collection Center (CGMCC), the deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, the deposit number is CGMCC No.30078, and the deposit date is March 21, 2024. During the fermentation process, the lactic acid bacteria XJ‑24 of the present invention not only grows and metabolizes to produce metabolites that inhibit the growth of Listeria monocytogenes, but also, when co-fermented with Listeria monocytogenes, it is not only not inhibited by Listeria monocytogenes, but the bacteria can also adhere to the surface of Listeria monocytogenes, effectively exerting an in situ inhibitory effect, and finally reducing the number of viable bacteria of Listeria monocytogenes to 0, thereby killing Listeria monocytogenes.